|
 Current shareholders have already committed to subscribing for an
aggregate of at least 15 million euros in the offering due to take
place in late September.
Nyxoah believes the proceeds, together with existing cash and
revenue, will meet its requirements for at least 12 months as it
seeks to commercialise its treatment, initially in certain European
countries.
Nyxoah is developing its neurostimulation therapy Genio and says it
is the first battery-free, minimally invasive and leadless
neurostimulator implant.
Obstructive sleep apnoea affects 936 million people worldwide aged
30 to 69, with 425 million suffering moderate to severe symptoms for
whom treatment would be required, Nyxoah said in a statement.
The company has obtained reimbursement status for patients in
Germany, recently secured approval from the U.S. Food and Drug
Administration to initiate a trial there and expects approval for
use in Australia later this year.
[to top of second column] |
Nyxoah has not decided how it might go about selling its product in the United
States.
Degroof Petercam NV/SA and Belfius Bank NV/SA are acting as Joint Global
Coordinators and Joint Bookrunners for the offering, set to consist of an
initial public offering in Belgium and placements of shares in the United States
and elsewhere.
($1 = 0.8458 euros)
(Reporting by Philip Blenkinsop; Editing by Kirsten Donovan)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
